AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30055940 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR1 inhibition (vorapaxar)
Number of subjects: 6177
Study 27930518 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of MSC transplantation and butylphthalide
Number of subjects: 42
Study 27930518 — intervention group
Group type: COMPARATOR
Intervention: MSC transplantation alone
Number of subjects: 42
Study 27930518 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy
Number of subjects: 42
Study 25051144 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-deposit method
Number of subjects: 45
Study 25051144 — intervention group
Group type: COMPARATOR
Intervention: Single-deposit method
Number of subjects: 45
Study 25051144 — intervention group
Group type: COMPARATOR
Intervention: Double-deposit method
Number of subjects: 45
Study 25051144 — intervention group
Group type: COMPARATOR
Intervention: Single-deposit or double-deposit groups
Number of subjects: 45
Study 22343174 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine 25 mg once daily
Number of subjects: 0
Study 22343174 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 0
Study 20066671 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 5 weeks
Number of subjects: 30
Study 20066671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) for 1 week
Number of subjects: 30
Study 17578661 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 0
Study 15881486 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 302
Study 15881486 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone/acetaminophen 10 mg/650 mg
Number of subjects: 302
Study 15881486 — intervention group
Group type: EXPERIMENTAL
Intervention: codeine/acetaminophen 60 mg/600 mg
Number of subjects: 302
Study 15881486 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302
Study 12361064 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniplate osteosynthesis according to Champy
Number of subjects: 22
Study 12361064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 10449889 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (Diovan(R))
Number of subjects: 0
Study 10449889 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 7590440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 29
Study 7590440 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 2183939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 30
Study 2183939 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate 2 gm twice daily
Number of subjects: 30
Study 2183939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 377081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen 500 mg once daily
Number of subjects: 240
Study 377081 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 or 100 mg
Number of subjects: 240
Study 377081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen and Hydrochlorothiazide
Number of subjects: 240
Study 377081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 240
Study 31601571 — intervention group
Group type: EXPERIMENTAL
Intervention: Rojiroti microfinance intervention
Number of subjects: 2469
Study 28973149 — intervention group
Group type: EXPERIMENTAL
Intervention: stAPP smartphone-based intervention (smartphone, smartphone app, and corresponding motion sensor)
Number of subjects: 58
Study 28973149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 27631594 — intervention group
Group type: EXPERIMENTAL
Intervention: Basket catheter
Number of subjects: 184
Study 27631594 — intervention group
Group type: COMPARATOR
Intervention: Balloon catheter
Number of subjects: 184
Study 28059433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 302
Study 28059433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 302
Study 28059433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 28059433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (both doses)
Number of subjects: 302
Study 25286684 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing Qi and Activating Blood treatment (Yu‐Ping‐Feng capsules and Fu‐Fang‐Dan‐Shen tablets for 3 months)
Number of subjects: 50
Study 25286684 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing Qi and Activating Blood treatment
Number of subjects: 50
Study 22326816 — intervention group
Group type: EXPERIMENTAL
Intervention: Case studies combined with concept maps (CSCM)
Number of subjects: 67
Study 22326816 — intervention group
Group type: COMPARATOR
Intervention: Case studies alone (CS)
Number of subjects: 67
Study 19393842 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 269
Study 19393842 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 269
Study 19393842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Besifloxacin and Vehicle)
Number of subjects: 269
Study 17202548 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (N=79)
Number of subjects: 143
Study 17202548 — intervention group
Group type: COMPARATOR
Intervention: Waiting list comparison group (N=64)
Number of subjects: 143
Study 16135469 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-modeling videotape (VID)
Number of subjects: 558
Study 16135469 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard print material, videotape, two sessions with a trained cancer educator, and informational workbook (EDU)
Number of subjects: 558
Study 16135469 — intervention group
Group type: COMPARATOR
Intervention: Standard National Cancer Institute print material (CTL)
Number of subjects: 558
Study 11975150 — intervention group
Group type: EXPERIMENTAL
Intervention: High control condition
Number of subjects: 40
Study 11975150 — intervention group
Group type: EXPERIMENTAL
Intervention: Low control condition
Number of subjects: 40
Study 9299914 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal Component Analysis (PCA)
Number of subjects: 0
Study 9299914 — intervention group
Group type: EXPERIMENTAL
Intervention: Möcks's Topographic Component Model (TCM)
Number of subjects: 0
Study 9299914 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations using seven imperfect rotations
Number of subjects: 0
Study 8196410 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling extrachannel points
Number of subjects: 20
Study 8196410 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (control)
Number of subjects: 20
Study 3595695 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (3 X 400 mg daily for 3 days) plus Methimazole (3 X 20 mg daily for 10 days)
Number of subjects: 10
Study 3595695 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Methimazole (3 X 20 mg daily for 10 days)
Number of subjects: 10
Study 31355873 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with medical management (EVT)
Number of subjects: 105
Study 31355873 — intervention group
Group type: COMPARATOR
Intervention: Medical management only (MM)
Number of subjects: 105
Study 29489494 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort extract LI160
Number of subjects: 247
Study 29489494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 26864951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus‐eluting stent (BP‐SES)
Number of subjects: 182
Study 26864951 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer everolimus‐eluting stent (PP‐EES)
Number of subjects: 182
Study 24757229 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated predictive low glucose pump suspension system
Number of subjects: 45
Study 24757229 — intervention group
Group type: COMPARATOR
Intervention: No pump suspension (control)
Number of subjects: 45
Study 24757229 — intervention group
Group type: COMPARATOR
Intervention: Control nights (no intervention)
Number of subjects: 45
Study 24757229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump suspension exceeding 2 hours
Number of subjects: 45
Study 24757229 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated pump suspension system
Number of subjects: 45
Study 22891219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 742
Study 22891219 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 742
Study 22891219 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet interventions (four diets differing in fat, protein, and carbohydrate proportions)
Number of subjects: 742
Study 20435275 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-oriented intervention group
Number of subjects: 808
Study 20435275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 808
Study 18585514 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9971
Study 18585514 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 9971
Study 18585514 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 9971
Study 18585514 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 9971
Study 18585514 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 9971
Study 15854139 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intravenous ascorbic acid
Number of subjects: 9
Study 15854139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15328062 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH infusion (10 microg/kg, 6‐min square wave pulse)
Number of subjects: 9
Study 15328062 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study 10752814 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (breathing exercises, huffing, and coughing) plus incentive spirometry
Number of subjects: 67
Study 10752814 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (breathing exercises, huffing, and coughing) alone
Number of subjects: 67
Study 10752814 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus incentive spirometry
Number of subjects: 67
Study 10752814 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 67
Study 9496559 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 mcg)
Number of subjects: 9
Study 8471373 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative indomethacin
Number of subjects: 0
Study 8471373 — intervention group
Group type: COMPARATOR
Intervention: Postoperative indomethacin
Number of subjects: 0
Study 4031109 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol
Number of subjects: 18
Study 4031109 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 18
Study 3064919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 40 mg three times a day
Number of subjects: 68
Study 3064919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31808598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bambuterol hydrochloride (10 mg, once daily, for 3 days)
Number of subjects: 51
Study 31808598 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 51
Study 30242962 — intervention group
Group type: EXPERIMENTAL
Intervention: NYX-2925 (50-1200 mg single-ascending dose and 150-900 mg multiple-ascending dose)
Number of subjects: 84
Study 30242962 — intervention group
Group type: EXPERIMENTAL
Intervention: NYX-2925
Number of subjects: 84
Study 31966779 — intervention group
Group type: EXPERIMENTAL
Intervention: Autolysis debridement and mechanical debridement
Number of subjects: 22
Study 26580240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times a day for 3 months
Number of subjects: 21
Study 26580240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 24007570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 200
Study 24007570 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 200
Study 21504952 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar perception training using a hardness discrimination task
Number of subjects: 46
Study 21504952 — intervention group
Group type: COMPARATOR
Intervention: Control group (simply remaining standing on foam rubber)
Number of subjects: 46
Study 21504952 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar perception training
Number of subjects: 46
Study 21504952 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 19082699 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitor perindopril
Number of subjects: 12218
Study 19082699 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors
Number of subjects: 12218
Study 19082699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic profiling
Number of subjects: 12218
Study 16390284 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 0
Study 14734956 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 14734956 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 11561868 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral proteolytic enzyme preparation (enzyme tablets t.i.d. starting 3 days prior to radiation therapy and continuing up to 5 days after completion)
Number of subjects: 100
Study 9301350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (400 micrograms/day)
Number of subjects: 23
Study 8421038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound control for closed femoral nailing
Number of subjects: 30
Study 8421038 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods with an image intensifier
Number of subjects: 30
Study 3717115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate and sodium phenylacetate
Number of subjects: 8
Study 3717115 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (lactulose or neomycin)
Number of subjects: 8
Study 29570907 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention with Lactobacilli reuteri (DSM 17938 and ATCC PTA 5289)
Number of subjects: 22
Study 29570907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28061543 — intervention group
Group type: EXPERIMENTAL
Intervention: GTDS (transdermal granisetron patch, 7 days)
Number of subjects: 313
Study 28061543 — intervention group
Group type: COMPARATOR
Intervention: Oral granisetron (2 mg/day, ≥2 days)
Number of subjects: 313
Study 28061543 — intervention group
Group type: EXPERIMENTAL
Intervention: GTDS and Oral granisetron
Number of subjects: 313
Study 25499944 — intervention group
Group type: EXPERIMENTAL
Intervention: 220.5 mg of cis-palmitoleic acid once per day for 30 days
Number of subjects: 60
Study 25499944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1000 mg of medium chain triglycerides) once per day for 30 days
Number of subjects: 60
Study 23841969 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video gaming (50-60 minutes/day, 4 days/week, for 5 weeks)
Number of subjects: 30
Study 23841969 — intervention group
Group type: COMPARATOR
Intervention: Normal activity (control group)
Number of subjects: 30
Study 20134177 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbotron training
Number of subjects: 15
Study 20134177 — intervention group
Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 15
Study 20134177 — intervention group
Group type: COMPARATOR
Intervention: Running training
Number of subjects: 15
Study 20134177 — intervention group
Group type: EXPERIMENTAL
Intervention: All training types
Number of subjects: 15
Study 18023435 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy for low sexual desire
Number of subjects: 0
Study 18023435 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous androgen levels
Number of subjects: 0
Study 18023435 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher endogenous serum androgen levels
Number of subjects: 0
Study 18023435 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgenic hormonal replacement regimens
Number of subjects: 0
Study 15722593 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral education (OPSMC)
Number of subjects: 470
Study 15722593 — intervention group
Group type: COMPARATOR
Intervention: Low T-score
Number of subjects: 470
Study 15722593 — intervention group
Group type: EXPERIMENTAL
Intervention: None (general findings)
Number of subjects: 470
Study 12878918 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 108
Study 12878918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 108
Study 12878918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Naltrexone and Acamprosate
Number of subjects: 108
Study 12878918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 12878918 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Management (MM)
Number of subjects: 108
Study 12878918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 108
Study 12878918 — intervention group
Group type: EXPERIMENTAL
Intervention: CBI alone without pills
Number of subjects: 108
Study 10479196 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (3 d/wk for 20 weeks, starting at 55% VO(2)max for 30 min/session, increasing to 75% VO(2)max for 50 min/session)
Number of subjects: 557
Study 8952583 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg oral dose)
Number of subjects: 6
Study 1784658 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete stem
Number of subjects: 166
Study 1784658 — intervention group
Group type: COMPARATOR
Intervention: Incomplete stem
Number of subjects: 166
Study 7259838 — intervention group
Group type: EXPERIMENTAL
Intervention: Single alkylating agent chemotherapy
Number of subjects: 51
Study 7259838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP)
Number of subjects: 51
Study 7259838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated whole body irradiation followed by low dose involved field irradiation
Number of subjects: 51
Study 7259838 — intervention group
Group type: COMPARATOR
Intervention: All treatment options
Number of subjects: 51
Study 31973700 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine/morphine (LM)
Number of subjects: 150
Study 31973700 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (L)
Number of subjects: 150
Study 31973700 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 150
Study 29785399 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) at 30 minutes post-breakfast (EX30)
Number of subjects: 26
Study 29785399 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) at 60 minutes post-breakfast (EX60)
Number of subjects: 26
Study 29785399 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) at 90 minutes post-breakfast (EX90)
Number of subjects: 26
Study 27457568 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Number of subjects: 60
Study 27457568 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study 24116959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab with immediate methotrexate withdrawal (arm 1)
Number of subjects: 489
Study 24116959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab with 4-week gradual methotrexate withdrawal (arm 2)
Number of subjects: 489
Study 22142548 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-paracentesis intravenous nutritional support with a balanced oral diet and a late-evening protein snack (Group A)
Number of subjects: 120
Study 22142548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional protocol without parenteral support (Group B)
Number of subjects: 120
Study 22142548 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium or sodium-free diet (Group C)
Number of subjects: 120
Study 20350360 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory ensheathing cells (OECs) transplantation, injected into the bilateral corona radiata in the frontal lobes
Number of subjects: 33
Study 20350360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OECs transplantation)
Number of subjects: 33
Study 20350360 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory ensheathing cells (OECs) transplantation
Number of subjects: 33
Study 17208951 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA therapy
Number of subjects: 0
Study 17208951 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA therapy in women with adrenal insufficiency
Number of subjects: 0
Study 17208951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15621325 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in water at a self-determined pace
Number of subjects: 16
Study 15621325 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in water with additional loads (8 kg)
Number of subjects: 16
Study 15621325 — intervention group
Group type: COMPARATOR
Intervention: Walking on land (slow walking)
Number of subjects: 16
Study 15621325 — intervention group
Group type: COMPARATOR
Intervention: Walking on land (fast walking)
Number of subjects: 16
Study 15621325 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in water (fast walking)
Number of subjects: 16
Study 12140146 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 116
Study 12140146 — intervention group
Group type: COMPARATOR
Intervention: Palliative care
Number of subjects: 116
Study 9927843 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0